F

Fate Therapeutics
D

FATE

1.23500
USD
-0.01
(-0.80%)
مغلق
حجم التداول
42,529
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
141,571,782
أصول ذات صلة
A
ARWR
-0.520
(-3.20%)
15.740 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
N
NTLA
0.830
(6.50%)
13.595 USD
R
RGEN
-0.200
(-0.16%)
121.670 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
المزيد
الأخبار المقالات

العنوان: Fate Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.